Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Trends in the market for antihypertensive drugs

Nature Reviews Drug Discovery volume 16, pages 309–310 (2017)Cite this article

Subjects

Hypertension, or prolonged and persistent elevation in blood pressure, is one of the most important risk factors for mortality and morbidity due to cardiovascular disease. An estimated one billion people are affected by hypertension worldwide and the condition accounts for more than half of the 17 million deaths caused by cardiovascular disease each year. Approximately 5% of hypertensive patients have an underlying cause (for example, kidney disease) for their disease, but the vast majority are diagnosed with 'essential hypertension' with unknown aetiology. Pulmonary arterial hypertension (PAH) is a subtype of hypertensive disease in the arteries connecting the right side of the heart to the lungs. It can be associated with other conditions, including connective tissue disease, and it has been the focus of efforts to develop PAH-specific interventions.

Current therapies

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Global sales of antihypertensive drugs.

Acknowledgements

The authors would like to thank Dr Sharmarke Mohamed, Khalifa University, Abu Dhabi, for his critical comments and feedback on the article.

Author information

Authors and Affiliations

  1. University College London Division of Surgery and Interventional Science, Royal Free NHS Trust Hospital Campus, Pond Street, London, NW3 2QG, Hampstead, UK

    M. Adam Ali & Salman Rizvi

  2. FirstWord Pharma, PSL Group, 75 Davies Street, London, W1K 5JN, UK

    Basharut A. Syed

Authors
  1. M. Adam Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Salman Rizvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Basharut A. Syed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Basharut A. Syed.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ali, M., Rizvi, S. & Syed, B. Trends in the market for antihypertensive drugs. Nat Rev Drug Discov 16, 309–310 (2017). https://doi.org/10.1038/nrd.2016.262

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2016.262

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research